The Manufacturers Life Insurance Company Trims Holdings in Labcorp Holdings Inc. $LH

The Manufacturers Life Insurance Company reduced its stake in Labcorp Holdings Inc. (NYSE:LH) by 8.0% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 43,723 shares of the medical research company’s stock after selling 3,779 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Labcorp were worth $11,666,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in LH. JPL Wealth Management LLC purchased a new stake in Labcorp in the third quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. purchased a new position in shares of Labcorp during the fourth quarter worth $26,000. Hilton Head Capital Partners LLC purchased a new position in shares of Labcorp during the fourth quarter worth $27,000. Eagle Bay Advisors LLC acquired a new stake in shares of Labcorp in the fourth quarter valued at $29,000. Finally, DV Equities LLC purchased a new stake in shares of Labcorp in the 4th quarter valued at $29,000. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp Price Performance

LH stock opened at $309.47 on Monday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.80 and a quick ratio of 1.53. The firm has a market capitalization of $25.38 billion, a P/E ratio of 25.60, a P/E/G ratio of 1.88 and a beta of 0.87. The business’s 50-day moving average is $274.71 and its two-hundred day moving average is $271.16. Labcorp Holdings Inc. has a 1 year low of $244.52 and a 1 year high of $316.11.

Labcorp (NYSE:LH) last announced its quarterly earnings data on Thursday, July 30th. The medical research company reported $4.99 EPS for the quarter, topping analysts’ consensus estimates of $4.78 by $0.21. Labcorp had a return on equity of 16.74% and a net margin of 6.99%.The business had revenue of $3.73 billion during the quarter, compared to the consensus estimate of $3.71 billion. During the same period in the previous year, the company posted $4.35 earnings per share. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Analysts anticipate that Labcorp Holdings Inc. will post 18.31 earnings per share for the current fiscal year.

Labcorp Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 28th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, August 28th. Labcorp’s payout ratio is 23.82%.

Insider Buying and Selling

In related news, EVP Kathryn W. Kyle sold 762 shares of the stock in a transaction on Monday, June 8th. The stock was sold at an average price of $263.89, for a total value of $201,084.18. Following the transaction, the executive vice president owned 3,813 shares of the company’s stock, valued at $1,006,212.57. This represents a 16.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Bryan T. Vaughn sold 234 shares of the firm’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a total value of $66,968.46. Following the completion of the sale, the executive vice president owned 6,746 shares in the company, valued at approximately $1,930,637.74. This represents a 3.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 6,991 shares of company stock worth $1,796,696. Corporate insiders own 0.84% of the company’s stock.

Key Headlines Impacting Labcorp

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Labcorp exceeded expectations in the second quarter, reporting adjusted EPS of $4.99 versus the $4.78 analyst consensus and revenue of $3.73 billion versus estimates of $3.71 billion. Revenue increased 5.8% year over year, supported by steady diagnostic-testing demand and growth in drug-development services. Reuters article
• Positive Sentiment: The company raised its 2026 adjusted EPS guidance to $18.10-$18.55, above the roughly $17.99-$18.00 consensus, while forecasting revenue of approximately $14.71 billion-$14.83 billion. Diagnostics Laboratories revenue rose 5.5%, and Biopharma Laboratory Services revenue increased 6.5%. Labcorp second-quarter results
• Positive Sentiment: Labcorp expanded its share-repurchase authorization by $1 billion, repurchased $353.8 million of stock during the quarter and paid $58.7 million in dividends. Truist Financial also raised its price target from $320 to $350 and assigned a “buy” rating, implying further upside from recent levels. Benzinga reference
• Neutral Sentiment: Management highlighted continued investment in oncology, consumer health and technology initiatives. The earnings call transcripts provide additional detail on demand trends, margins and the updated outlook. Labcorp Q2 earnings call transcript
• Negative Sentiment: Despite the earnings and revenue beats, LH shares fell in premarket trading and remain lower in active trading. The reaction indicates that investors may have viewed the results and raised outlook as insufficient relative to elevated expectations and the stock’s recent rally toward its 52-week high. Zacks market reaction
• Negative Sentiment: Recent insider-trading data shows company insiders made multiple sales and no purchases over the past six months, a potential sentiment headwind, although the transactions do not necessarily reflect management’s outlook. Quiver Quantitative report

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Robert W. Baird set a $352.00 target price on Labcorp in a research note on Friday. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $306.00 price target on shares of Labcorp in a research note on Friday. Barclays increased their price target on shares of Labcorp from $290.00 to $320.00 and gave the stock an “equal weight” rating in a research report on Thursday. Evercore reissued an “outperform” rating and issued a $300.00 price objective on shares of Labcorp in a research note on Wednesday, April 8th. Finally, Truist Financial upped their target price on shares of Labcorp from $320.00 to $350.00 and gave the stock a “buy” rating in a research note on Friday. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Labcorp has an average rating of “Moderate Buy” and a consensus target price of $323.27.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.